Left Atrial Appendage Closure vs. Novel Anticoagulation Agents in Atrial Fibrillation
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It plans to enroll 400 participants.
Also called NCT02426944
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose prevention
- Phase
- Phase 4
- Enrolled
- 400 participants
- Registry
-
NCT02426944
-
- Other papers using this trial's data
- 4-Year Outcomes After Left Atrial Appendage Closure Versus Nonwarfarin Oral Anticoagulation for Atrial Fibrillation
- Left Atrial Appendage Closure Versus Direct Oral Anticoagulants in High-Risk Patients With Atrial Fibrillation
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Czechia
- Registry status
- Completed
Technical summary
Registry record NCT02426944. Randomized; no masking; primary purpose prevention. Start 2015-10-13 (actual); primary completion 2019-07-20 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Left Atrial Appendage Closure vs. Novel Anticoagulation Agents in Atrial Fibrillation
- Acronym
- PRAGUE-17
- Condition
- Atrial Fibrillation
- Intervention (Drug)
- NOAC
- Intervention (Device)
- Left atrial appendage closure
- Lead sponsor
- Charles University, Czech Republic
- Collaborator
- Ministry of Health, Czech Republic
Record details
- Record id
cardio:ct-nct02426944- Content hash
c3f7da45e32582c133f6e5c6cde103b050be122a021ed47509ff608b43f6a6a0